| Literature DB >> 28829391 |
Susanne Roosing1,2, Frans P M Cremers3,4, Frans C C Riemslag5,6, Marijke N Zonneveld-Vrieling7, Herman E Talsma8,9, Francoise J M Klessens-Godfroy10, Anneke I den Hollander11,12,13, L Ingeborgh van den Born14.
Abstract
PURPOSE: To identify the gene defect and to study the clinical characteristics and natural course of disease in a family originally diagnosed with oligocone trichromacy (OT), a rare congenital cone dysfunction syndrome.Entities:
Keywords: CEP290; ciliopathies; cone dysfunction syndrome; long-term follow up; oligocone trichromacy
Year: 2017 PMID: 28829391 PMCID: PMC5575671 DOI: 10.3390/genes8080208
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Figure 1Retinal imaging of two individuals with CEP290 variants A–B, Clinical characteristics of patient II-1 of family A. (A) The fundus photograph showed a pink optic disc and mildly attenuated vessels. The retinal pigment epithelium (RPE) had a coarse-grained aspect in the posterior pole and mid-periphery, and a faintly recognizable foveola reflex with a subtle indication of bull’s eye-like maculopathy. (B) Fundus autofluorescence (FAF) revealed a relatively normal appearance. C–G, Clinical characteristics of patient II-2 of family A. (C) Fundoscopy displayed a pink, myopic optic disc, mildly attenuated vessels and subtle RPE changes in the macula with a faintly recognizable foveola reflex and thinning of the perimacular RPE. (D) Fundus autofluorescence of the right eye revealed a double hyperautofluorescent ring and hypoautofluorescent spots along and inferior to the inferior vascular arcade. (E) Optical coherence tomography (OCT) of the left eye displayed no discernible photoreceptor complexes at the macula, but recognizable outer retinal layers at the peripheral part of the scan. (F) Fundus autofluorescence of the left eye revealed a double faint hyperautofluorescent ring and hypoautofluorescent spots along and inferior of the inferior vascular arcade as well as in the macula. (G) A compilation of fundus photographs of the left eye of II-2 showed a pink and myopic optic disc and mildly attenuated vessels. A faintly recognizable foveola reflex was noted, as well as perifoveal RPE atrophy. Mild RPE changes in the superior quadrants and more pronounced RPE atrophy in inferior quadrants with bone-spicule pigmentations were documented.
Clinical characteristics of two patients with variants in CEP290.
| Patient ID | II-1 | II-2 |
|---|---|---|
| Sex | Female | Male |
| Age at diagnosis | 3 | 2 |
| Age recent examination | 46 | 45 |
| Nystagmus | Present | Present |
| Visual acuity RE | 20/100 | 20/80 |
| Visual acuity LE | 20/100 | 20/160 |
| Refraction | RE: +1.25–2.25 × 19; LE: −0.25–3.00 × 170 | RE: −14.25–1.75 × 5; LE: −10.25–2.25 × 155 |
| Lens | Clear | Clear |
| Fundus | Pink optic discs, mildly attenuated arterioles, coarse-grained aspect RPE posterior pole and mid-periphery superior quadrants, faintly recognizable foveola reflex BE with subtle indication for bull’s eye-like maculopathy, RPE atrophy in far periphery of superior quadrants, RPE atrophy in mid- and far periphery of inferior quadrants with scarce bone-spicule pigmentations | Pink, myopic optic discs, mildly attenuated arterioles, subtle RPE alterations macula RE, ring-shaped atrophy surrounding the fovea LE, faintly recognizable foveola reflex BE, perimacular RPE atrophy, mild RPE changes superior quadrants, RPE atrophy inferior quadrants with bone-spicule pigmentations |
| Fundus autofluorescence | Relatively normal | Double hyperautofluorescent ring, hypoautofluorescent spots along and inferior to the inferior vascular arcade BE, and in macula LE |
| OCT | Failed | No discernible photoreceptor complexes at the macula, but present at the peripheral part of the scan. |
| Color vision (Panel D-15) | Saturated: normal | RE: de- and saturated: multiple errors mainly in tritan axis |
| Visual field (Goldmann) | Radius < 100 | Altitudinal defect BE, partially including the center RE, central scotoma LE |
| ERG | Mildly reduced isolated rod responses with significantly reduced ‘mixed’ responses | Significantly reduced isolated rod and ‘mixed’ responses |
| ERG | Non-recordable | Non-recordable |
| Miscellaneous | Anorexia, depressions, followed by the diagnosis of schizofrenia at age 29 | None |
BE = both eyes, ERG = electroretinogram, LE = left eye, OCT = optical coherence tomography, RE = right eye, RPE = retinal pigment epithelium.
Figure 2Pedigree and mRNA analysis of individuals with oligocone trichromacy (OT) carrying the heterozygous CEP290 variants c.4723A>T and c.415C>T. (A) The pedigree with OT and the segregation of CEP290 variants c.415C>T (p.(Arg151*), (M1) and c.4723A>T (p.(Lys1575*), (M2); (B) CEP290 cDNA analysis of the effect of the c.4723A>T variant on splicing of exon 36 in the patient cell lines treated with (+) or without (−) cycloheximide (CHX) to prevent degradation by nonsense-mediated decay (NMD) versus non-treated control cell lines (C1–C3). Agarose gel electrophoresis revealed a major 432 bp product representing the normal-sized transcript in all tested samples. Hence, the difference of band intensity (@) between treated and untreated samples in the affected individuals can be explained by the partial effect of NMD on the mRNAs carrying the p.(Arg151*) and p.(Lys1575*) variants. An aberrant product (*) is seen in the affected persons at 324 bp, whereas this product was not found in controls (C1–C3). This product size corresponds to a transcript lacking exon 36. The smaller-sized fragments represent nonspecific products as observed by sequencing. The comparison for input was made by the analysis of the housekeeping gene GUSB; (C) Sequence analysis of the abundant cDNA product in the CHX treated samples shows the exon transition from 35 to 36 with apparently equal amounts of mRNAs carrying the p.(Lys1575*) mutation and the mRNAs derived from the three c.415C>T alleles (see panel F). (D) Sequences of the aberrant product from exon 35 to 37, skipping exon 36. (E) Sequence analysis of the CHX untreated normal-sized mRNA product shows a reduced presence of the mutant allele due to partial NMD, visible by a reduced peak size of the mutant T-allele (M2@) compared to the wild-type A-allele. (F) Schematic representation of the effect of the CEP290 stopmutations. The c.415C>T variant results in three mRNA variants, one of which carries the truncating mutation and the other two carrying in-frame deletions. The c.4723A>T variant results in two mRNA variants, a major product carrying the p.(Lys1575*) truncating mutation and a minor product carrying an in-frame deletion. Both variants are therefore considered hypomorphic variants.
Individuals harboring the c.4723A>T mutation in CEP290.
| First Allele | Second Allele | |||||||
|---|---|---|---|---|---|---|---|---|
| Sample ID | Diagnosis | DNA Variant | Predicted Protein Variant | Predicted Proteins Based on RNA Study | DNA Variant | Predicted Protein Variant | Predicted Proteins Based on RNA Study | Ref. |
| Family A | OT | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] # | c.451C>T | p.(Arg151*) | p.[Arg151*, Leu148_Glu165del, Leu148_Lys172del] | This study |
| 809 | LCA | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.1709C>G | p.(Ser570*) | ND | [ |
| LCA-6 | LCA | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.2991+1655A>G | p.(Cys998*) | p.[Cys998*, =] $ | [ |
| LCA-7 | LCA | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.2991+1655A>G | p.(Cys998*) | p.[Cys998*, =] | [ |
| LCA-8 | LCA | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.2991+1655A>G | p.(Cys998*) | p.[Cys998*, =] | [ |
| LCA | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.2991+1655A>G | p.(Cys998*) | p.[Cys998*, =] | [ | |
| LCA-24 | LCA | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.4696G>C | p.(Ala1556Pro) | ND | [ |
| COR031/CORS1 | CORS | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.4393C>T | p.(Arg1465*) | ND | [ |
| SLS-2 | SLSN | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.4393C>T | p.(Arg1465*) | ND | [ |
| SLS-3 | SLSN | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.4393C>T | p.(Arg1465*) | ND | [ |
| F283-21 | SLSN | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.1984C>T | p.(Gln662*) | ND | [ |
| A3100-21 | SLSN | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.1987A>T | p.(Lys663*) | ND | [ |
| A1210-21 | SLSN | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.3802C>T | p.(Gln1268*) | ND | [ |
| F118-21 | SLSN | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.4452_4455delAGAA | p.(Lys1484Asnfs*4) | ND | [ |
| A1712-21 | SLSN | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.1189+1A>G | p.(?) | ND | [ |
| 1 | LCA | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | [ |
| 2 | LCA | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | [ |
| 738 | LCA | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | [ |
| 848 | LCA | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | [ |
| 258 | LCA | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | [ |
| 419 | LCA | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | [ |
| LEP | LCA | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | [ |
| LCA-25 | LCA | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | [ |
| 623 | JBTS+retina | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | c.4723A>T | p.(Lys1575*) | p.[Lys1575*, Glu1569_Trp1604del] | [ |
Patient LCA-7 and LCA-25 are distantly related; LCA = Leber congenital amaurosis; SLSN = Senior loken; CORS = Cerebello-oculo-renal syndrome; JBTS+retina = Joubert syndrome with retinal involvement; # the mRNA carrying the p.(Lys1575*) mutation is the major product and the mRNA carrying the in-frame amino acid deletion p.(Glu1569_Trp1604del) is the minor product (see Figure 2); ND = not determined; $ = approximately equal amounts of mRNA were detected that contained an intronic insertion resulting in the p.(Cys998*) stop mutation and normal CEP290 transcript.